Cybin Inc. Partners for CYB003 Clinical Trials
Ticker: HELP · Form: 6-K · Filed: Jan 15, 2025 · CIK: 1833141
| Field | Detail |
|---|---|
| Company | Cybin INC. (HELP) |
| Form Type | 6-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: collaboration, clinical-trials, pharmaceuticals, mental-health
TL;DR
Cybin inks deal with big pharma to fast-track CYB003 trials for depression.
AI Summary
On January 15, 2025, Cybin Inc. filed a Form 6-K, announcing a strategic clinical development collaboration with a major pharmaceutical company. This collaboration focuses on advancing Cybin's deuterated psilocybin therapy, CYB003, through late-stage clinical trials. The partnership aims to accelerate the development and potential commercialization of CYB003 for treating major depressive disorder.
Why It Matters
This collaboration signifies a major step for Cybin Inc. in advancing its novel psychedelic therapy, potentially bringing a new treatment option for major depressive disorder closer to market.
Risk Assessment
Risk Level: medium — The company is in the clinical trial phase for a novel therapeutic, which carries inherent risks related to trial success, regulatory approval, and market adoption.
Key Players & Entities
- Cybin Inc. (company) — Registrant
- CYB003 (drug) — Deuterated psilocybin therapy
- Doug Drysdale (person) — Chief Executive Officer
- January 15, 2025 (date) — Filing date and news release date
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K filing is to report a news release dated January 15, 2025, announcing a strategic clinical development collaboration for Cybin Inc.'s CYB003.
What is CYB003?
CYB003 is Cybin Inc.'s deuterated psilocybin therapy being developed for potential treatment of major depressive disorder.
Who signed the report on behalf of Cybin Inc.?
Doug Drysdale, Chief Executive Officer, signed the report on behalf of Cybin Inc.
What is Cybin Inc.'s fiscal year end?
Cybin Inc.'s fiscal year ends on March 31st.
What is the Commission File Number for Cybin Inc.?
The Commission File Number for Cybin Inc. is 001-40673.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2025-01-15 15:29:17
Filing Documents
- cybininc-form6xk01x15x2025.htm (6-K) — 11KB
- cybinlaunchesstrategicclin.htm (EX-99.1) — 18KB
- image_0.jpg (GRAPHIC) — 14KB
- 0001628280-25-001592.txt ( ) — 49KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYBIN INC. (Registrant) Date January 15, 2025 By s Doug Drysdale Name Doug Drysdale Title Chief Executive Officer EXHIBIT INDEX 99.1 News Release dated January 15, 2025